MDMA-Assisted Therapy for PTSD: An Update on the Progress of MAPS’ Pivotal Program

Our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD is well underway, with enrollment of more than two-thirds  of the participants needed to complete the study. We have also begun our long term follow up study, in which we will gather data from past participants. 

MAPS conducts clinical trials in the U.S. under the guidance and regulations of the U.S. Food and Drug Administration (FDA) in collaboration with federal regulators, including the Drug Enforcement Administration (DEA) and appropriate regulatory bodies in other countries. To learn more about our clinical trials or apply to be a study participant, visit our website. Additional information can be found at